The USPTO has ruled that AI cannot be named as a patent inventor, aligning with recent decisions by UKIPO and EPO. The Indian Patent Office has extended the SIPP Scheme, while CSIR allows deferred payments for COVID-19 related IP. Key updates also include Gilead’s global access strategy for Remdesivir and new developments from IPOS Singapore and USTR.
Read more about AI cannot be an inventor rules USPTO, IPO extends SIPP Scheme and other patent news